ATLANTA, Nov. 18, 2025 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Skye Bioscience, Inc. ("Skye" or the "Company") (NASDAQ: SKYE). The lawsuit alleges that Defendants made materially false and/or misleading statements and/or failed to disclose key facts, including allegations that:  (1) nimacimab was less effective than Defendants had led investors to believe; (2) accordingly, nimacimab's clinical, regulatory, and commercial prospects were overstated; and (3) as a result, D ...